Phaseline

Targets › CD27

CD27 (CD27 antigen): drug programs, companies and trials

7 programs from 6 companies in 8 trials: 4 Phase 2, 3 Phase 1, 1 Phase 3; Oncology, Immunology, Genitourinary; next expected readout Mar 2027.

Costimulatory immune-checkpoint receptor expressed at the surface of T-cells, NK-cells and B-cells which binds to and is activated by its ligand CD70/CD27L expressed by B-cells. The CD70-CD27 signaling pathway mediates antigen-specific T-cell activation and expansion which in turn provides immune surveillance of B-cells. (UniProt, P26842)

Open in Phaseline: the race on CD27, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Alpine Immune SciencesPovetacicept (ALPN-303)
Dual CD27/CD70 co-stimulation inhibitor
CD27, CD70Phase 3Immunoglobulin A NephropathyJan 2028
Annick Desjardins, MDVarlilumab
CD27 antigen agonist
CD27Phase 2GlioblastomaMar 2027
Robert SamsteinNadunolimab
agonist of CD27, a TNF superfamily co-stimulatory receptor
CD27Phase 2High-risk Lung NodulesDec 2027
National Cancer Institute (NCI)Varlilumab
CD27 antigen agonist
CD27Phase 2ALK-Positive Large B-Cell Lymphoma; Metastatic Distal Bile Duct Adenocarcinoma–
Beijing Tongren HospitalStapokibart
CD27 agonist antibody
CD27Phase 1HNSCCJun 2027
Alpine Immune SciencesPovetacicept (ALPN-303)
CD27 costimulatory molecule inhibitor
CD27Phase 1Lupus NephritisMar 2028
Xilio DevelopmentXTX501
CD27 agonist
CD27Phase 1Metastatic NSCLC - Non-Small Cell Lung CancerNov 2029

Conditions

Lupus Nephritis (1) ALK-Positive Large B-Cell Lymphoma (1) Metastatic Distal Bile Duct Adenocarcinoma (1) HNSCC (1) Metastatic NSCLC - Non-Small Cell Lung Cancer (1) Immunoglobulin A Nephropathy (1) High-risk Lung Nodules (1) Glioblastoma (1)

Modalities

antibody (4), mixed (2), small molecule (1)

Companies

Alpine Immune Sciences (2) National Cancer Institute (NCI) (1) Beijing Tongren Hospital (1) Xilio Development (1) Robert Samstein (1) Annick Desjardins, MD (1)

Related targets

CD70 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.